Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...

Descripción completa

Detalles Bibliográficos
Autores principales: Medhora, Meetha, Phadnis, Preeya, Narayanan, Jayashree, Gasperetti, Tracy, Zielonka, Jacek, Moulder, John E., Fish, Brian L., Szabo, Aniko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111401/
https://www.ncbi.nlm.nih.gov/pubmed/33986677
http://dx.doi.org/10.3389/fphar.2021.646076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111401/
https://www.ncbi.nlm.nih.gov/pubmed/33986677
http://dx.doi.org/10.3389/fphar.2021.646076

Ejemplares similares